Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Carcinoma, Renal Cell 23Sarcoma 18Neoplasms 8Neoplasm Metastasis 8Breast Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Fallopian Tube Neoplasms 6Liposarcoma 5Leiomyosarcoma 5Hemangiosarcoma 5Sarcoma, Synovial 4Neurofibrosarcoma 4Lung Neoplasms 4Kidney Neoplasms 4Histiocytoma, Malignant Fibrous 4Urinary Bladder Neoplasms 3Recurrence 3Prostatic Neoplasms 3Glioblastoma 3Thyroid Carcinoma, Anaplastic 2Small Cell Lung Carcinoma 2Sarcoma, Alveolar Soft Part 2Pancreatic Neoplasms 2Neuroendocrine Tumors 2Melanoma 2Gliosarcoma 2Fibrosarcoma 2Dermatofibrosarcoma 2Clear-cell metastatic renal cell carcinoma 2

Interventions

pazopanib 1lenvatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Paraganglioma, Extra-Adrenal × pazopanib × Clear all
NCT01340794 2017-09-21

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

National Cancer Institute (NCI)

Phase 2 Terminated
7 enrolled 8 charts
CNSEndocrine

Paraganglioma, Paraganglioma, Extra-Adrenal, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡